C41.2 Insurance Policy Changes

ICD-10 C41.2 is officially defined as "Malignant neoplasm of vertebral column." code C41.2 is referenced in 7 tracked payer policy changes from Excellus BlueCross BlueShield, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C41.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Oct 15, 2026Medium impact
Percutaneous Vertebroplasty/Mechanical Vertebral Augmentation and Percutaneous Sacroplasty - (Effective Date - 2026-10-15) 6.01.17
Vertebral augmentation with PMMA cement under imaging guidance is medically necessary for prophylactic vertebroplasty to facilitate fusion surgery, and for malignant conditions including osteolytic metastases, destruction of a vertebral body by multiple myeloma, or primary malignant neoplasm of bone or bone marrow with daily clinically significant pain. For non-malignant conditions it is medically necessary for osteoporotic or osteolytic vertebral compression fractures, aggressive space-occupying lesions (hemangioma or eosinophilic granuloma), osteonecrotic (Kummel disease) fractures, and steroid-induced fractures when imaging matches symptoms and exam findings and the pain duration and treatment criteria are met. Vertebral augmentation is not medically necessary with listed contraindications such as allergy to materials, uncorrected coagulation disorder or anticoagulation therapy, active infection, or active osteomyelitis of the target vertebra, and percutaneous sacroplasty is investigational for all indications.
Excellus BlueCross BlueShield · Effective Nov 16, 2025Medium impact
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy 6.01.12
Excellus BlueCross BlueShield stereotactic radiosurgery and stereotactic body radiation therapy medical policy 6.01.12 has a current effective date of November 16, 2025. Its October 16, 2025 annual review removed life expectancy criteria from the policy criteria. SRS is considered medically appropriate for specified benign, brain and neurologic indications, SBRT is considered medically appropriate for specified extracranial cancers and oligometastatic disease, and SBRT is considered not medically necessary for indications including extrahepatic bile duct cancer, gallbladder cancer and chronic pain.
Aetna · Identified Aug 19, 2026Medium impact
Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) of the Spine (CPB 0236, reviewed 2026-04-09)
Aetna's clinical policy bulletin covers magnetic resonance imaging (MRI) and computed tomography (CT) of the spine and lists the indications it considers medically necessary. These include clinical evidence of spinal stenosis, clinical suspicion of spinal cord or cauda equina compression, congenital anomalies or deformities of the spine, and known or suspected myelopathy when MRI of the brain is negative or symptoms mimic other spinal or brainstem lesions. The bulletin also lists persistent back or neck pain with radiculopathy and objective motor or reflex changes in the specific nerve root distribution with no improvement after 6 weeks of conservative therapy, spondylolisthesis and degenerative disease of the spine that has not responded to 4 weeks of conservative therapy, suspected spinal fracture or dislocation secondary to trauma when plain films are not conclusive, suspected spinal cord injury secondary to trauma, and suspected infectious process or spinal tumors. Aetna considers BoneMRI (MRI-based synthetic CT) experimental, investigational or unproven for pre-operative assessment and surgical planning of the spine and pelvis and for diagnosing or monitoring tumors. Aetna considers MRI and CT of the spine experimental, investigational or unproven for all other indications not listed, and considers MRI for further evaluation of unstable injury in neurologically intact individuals with blunt trauma after a negative cervical spine CT not medically necessary.
Aetna · Identified Aug 17, 2026Medium impact
Spinal Surgery: Laminectomy and Fusion (CPB 0743, reviewed 2026-07-30)
Aetna's Clinical Policy Bulletin 0743 sets medical necessity criteria for cervical, thoracic and lumbar laminectomy, laminoplasty, spinal fusion, vertebral corpectomy, and removal of spinal instrumentation. Most covered indications require advanced imaging (CT or MRI) showing at least moderate central, lateral recess or foraminal stenosis, or nerve root or spinal cord compression, at the level matching the clinical findings, and failure of at least 6 weeks of conservative therapy, or 3 months for certain fusion indications such as scoliosis, kyphosis and sub-axial instability. Computer-assisted surgical navigation is approvable only when fusion implants are placed during surgery, and it is not approvable during routine decompression surgery.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Minimally Invasive Approaches to Vertebral Fractures and Osteolytic Lesions of the Spine
Percutaneous vertebroplasty may be considered medically necessary for symptomatic osteoporotic vertebral fractures that have failed to respond to conservative treatment (such as analgesics, physical therapy and rest) for at least 6 weeks, for symptomatic osteoporotic fractures less than 6 weeks old that have led to hospitalization or persist at a level that prevents ambulation, and for severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies. Balloon kyphoplasty and mechanical vertebral augmentation with an FDA-cleared device follow similar criteria, while radiofrequency kyphoplasty and percutaneous sacroplasty are considered investigational. Investigational treatments are not considered medically necessary.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions
Charged-particle irradiation with proton or helium ion beams may be considered medically necessary for primary therapy of uveal tract melanoma meeting the listed size and metastasis criteria, for postoperative therapy after biopsy or partial resection of skull-base chordoma, low-grade chondrosarcoma or cervical spine lesions with residual localized tumor, and for pediatric central nervous system tumors. It may also be considered medically necessary where photon-based radiotherapy cannot meet normal tissue dose-volume constraints, including curative treatment of primary or benign solid pediatric non-CNS tumors such as Ewing sarcoma, nonmetastatic primary non-small cell lung cancer, and head and neck cancers. Clinically localized prostate cancer and non-curative treatment of these pediatric tumors and non-small cell lung cancer are considered investigational.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Magnetic Resonance-Guided Focused Ultrasound
Magnetic resonance-guided focused ultrasound may be considered medically necessary for pain palliation in adults with metastatic bone cancer who have failed or are not candidates for radiotherapy, and for medicine-refractory essential tremors. It is considered investigational for uterine fibroids, for other tumors such as brain, prostate, breast, and desmoid tumors, and for medication-refractory tremor dominant Parkinson disease. The policy history notes that CPT code 61715 for MRI guided focused ultrasound high intensity stereotactic intracranial ablation was effective 01/01/2025.

Watch C41.2

Get one email when a payer policy names C41.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code C41.2?

There are 7 tracked policy changes affecting code C41.2, including updates from Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C41.2?

Payers that have issued tracked updates for code C41.2 include: Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code C41.2 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C41.2. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C41.2?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Percutaneous Vertebroplasty/Mechanical Vertebral Augmentation and Percutaneous Sacroplasty - (Effective Date - 2026-10-15) 6.01.17

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy 6.01.12

Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) of the Spine (CPB 0236, reviewed 2026-04-09)

Spinal Surgery: Laminectomy and Fusion (CPB 0743, reviewed 2026-07-30)

Minimally Invasive Approaches to Vertebral Fractures and Osteolytic Lesions of the Spine

Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Magnetic Resonance-Guided Focused Ultrasound

What insurance policy changes affect code C41.2?

Which payers have updated policy for code C41.2?

How do I get notified when code C41.2 policy changes?

Why do payers change policies for code C41.2?